Filter by

Type of content

Include documents

Categories
Document type
Topics
Responsible body
Last updated
First published

Search results (28205)

Website outages and upgrades

The European Medicines Agency (EMA) makes upgrades to this website from time to time, to improve user experience. During these upgrades, the website is unavailable for a short period of time, outside of EMA working hours. This page lists when we are planning the next outage and the main improvements made.

Last updated: 22 June 2026
Corporate
Winrevair
INN or common name:sotatercept
Therapeutic area (MeSH):Hypertension, Pulmonary
Marketing authorisation issued:
Last updated:19 June 2026
Revision: 5
Additional monitoring
Orphan
PRIME: priority medicine
MedicineHumanAuthorised
Nobivac NXT HCPFeLV
INN or common name:feline calicivirosis, feline rhinotracheitis, feline panleucopenia (live) and feline leukemia (RNA replicon particle) vaccine
Opinion adopted:
Last updated:19 June 2026
MedicineVeterinaryOpinion
Nobivac NXT HCPChFeLV
INN or common name:feline calicivirosis, feline rhinotracheitis, feline panleucopenia, feline chlamydiosis (live) and feline leukemia (RNA replicon particle) vaccine
Opinion adopted:
Last updated:19 June 2026
MedicineVeterinaryOpinion
Scovella
INN or common name:velagliflozin
Opinion adopted:
Last updated:19 June 2026
MedicineVeterinaryOpinion
Nobivac NXT FeLV
INN or common name:feline leukemia (RNA particle) vaccine
Opinion adopted:
Last updated:19 June 2026
MedicineVeterinaryOpinion
EMA/PE/0000231366 - paediatric investigation plan
Active substance: efgartigimod alfa
Therapeutic area: Nervous system disorders
Pharmaceutical form(s): Concentrate for solution for infusion
Route(s) of administration: Intravenous use
Decision number: P/0298/2024
Decision date: 21 March 2025
Decision type: PM: decision on the application for modification of an agreed PIP
Compliance check done: No
Last updated: 19 June 2026
PIPHuman